

Resource Summary Report

Generated by PRECISE-TBI on Sep 1, 2026

Phospho-GSK-3 (Ser9) Antibody

RRID:AB_331405

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9336, RRID:AB_331405

Antibody Information

URL: http://antibodyregistry.org/AB_331405

Proper Citation: Cell Signaling Technology Cat# 9336, RRID:AB_331405

Target Antigen: Phospho-GSK-3 (Ser9)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W. Consolidation: AB_331406.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-GSK-3 (Ser9) Antibody

Description: This polyclonal targets Phospho-GSK-3 (Ser9)

Target Organism: b, rat, h, m, mouse, r, zebrafishfish, bovine, z, human, mk

Antibody ID: AB_331405

Vendor: Cell Signaling Technology

Catalog Number: 9336

Alternative Catalog Numbers: 9336S, 9336L

Record Creation Time: 20250819T225130+0000

Record Last Update: 20250820T033123+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-GSK-3 (Ser9) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 83 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Yadav K, et al. (2026) Therapeutic targeting of GSK-3 β activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ-2412, a novel sunitinib analogue. British journal of pharmacology, 183(15), 4196.

Matmat K, et al. (2026) SIRT1 mediates brain metabolic and developmental consequences of methionine synthase deficiency in inborn errors of cobalamin metabolism. Cell reports. Medicine, 7(3), 102643.

Ishikawa KI, et al. (2026) Suppression of ATM kinase signaling accelerates cellular senescence. Stem cell reports, 21(7), 102956.

Xu H, et al. (2026) Panx1 deficiency exacerbates GAN diet-induced obesity by destabilizing β -catenin via GSK3 β . iScience, 29(4), 115098.

Jeong YH, et al. (2025) Spirodelae Herba ethanol extract attenuates neurotoxicity in hippocampal cells and improves scopolamine-induced cognitive impairment in mice. Frontiers in pharmacology, 16, 1638068.

McDonald PC, et al. (2025) Neutrophil extracellular trap gene expression signatures identify prognostic and targetable signaling axes for inhibiting pancreatic tumour metastasis. Communications biology, 8(1), 1006.

Zhang YP, et al. (2025) PAI-1-driven SFRP2^{high} cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy. Cancer cell, 43(5), 856.

Farhangdoost N, et al. (2025) Lithium partially rescues gene expression and enhancer activity from heterozygous knockout of AKAP11 while inducing novel differential changes. Scientific reports, 15(1), 37844.

Li E, et al. (2025) CRISPRi-based screens in iAssembloids to elucidate neuron-glia interactions. *Neuron*, 113(5), 701.

Zheng S, et al. (2025) Phosphorylation of plectin by Akt3 promotes triple-negative breast cancer cell invasive migration. *iScience*, 28(10), 113552.

Chocarro-Calvo A, et al. (2025) Fatty acid uptake activates an AXL-CAV1- β -catenin axis to drive melanoma progression. *Genes & development*, 39(7-8), 463.

KrauB D, et al. (2025) EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer. *EMBO molecular medicine*, 17(6), 1355.

La Barbera L, et al. (2025) Midbrain degeneration triggers astrocyte reactivity and tau pathology in experimental Alzheimer's Disease. *Molecular neurodegeneration*, 20(1), 105.

Chocarro-Calvo A, et al. (2024) Phenotype-specific melanoma uptake of fatty acid from human adipocytes activates AXL and CAV1-dependent β -catenin nuclear accumulation. *bioRxiv* : the preprint server for biology.

Chang Y, et al. (2024) Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition. *Cell reports. Medicine*, 5(10), 101752.

Kopsidas CA, et al. (2024) Sustained generation of neurons destined for neocortex with oxidative metabolic upregulation upon filamin abrogation. *iScience*, 27(7), 110199.

Deka A, et al. (2024) Non-canonical NF- κ B signaling limits the tolerogenic β -catenin-Raldh2 axis in gut dendritic cells to exacerbate intestinal pathologies. *The EMBO journal*, 43(18), 3895.

Liu X, et al. (2024) The relevance between abnormally elevated serum ceramide and cognitive impairment in Alzheimer's disease model mice and its mechanism. *Psychopharmacology*, 241(3), 525.

Sharma R, et al. (2024) Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981. *iScience*, 27(11), 111133.

Torres JA, et al. (2024) β -hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney disease. *iScience*, 27(9), 110773.